Issued 2026-08-13 at $56.53 · now $55.87 (2026-08-13, −1.2% since)
Based on its own history, a month from the 2026-08-13 close, IONS has typically landed between $48.08 and $66.98 — a range of −14.9% to +18.5% from the issuance price $56.53.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,980 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($56.53) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where IONS has typically landed a month from the 2026-08-13 close of $56.53 — the range is history, not a prediction.
- now $55.87 (-1.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $56.88 (+0.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $53.27–$60.49
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $48.08–$66.98
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2016-04-27 | −48.4% | −48.4% | +0.0% |
| 2016-04-28 | −46.3% | −47.9% | +0.0% |
| 2016-04-29 | −44.6% | −47.9% | +0.0% |
| 3 best | |||
| 2016-10-27 | +78.1% | +0.0% | +87.5% |
| 2016-10-28 | +77.3% | −0.4% | +84.6% |
| 2016-11-04 | +74.9% | +0.0% | +77.5% |
4,980 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 3 primary completion: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) (source, as of 2026-08-14)
- February 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 (source, as of 2026-08-14)
- March 2027 — Trial primary completion: Phase 3 primary completion: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 3 primary completion: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (source, as of 2026-08-14)
- August 2027 — Trial primary completion: Phase 3 primary completion: REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome (source, as of 2026-08-14)
- September 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) (source, as of 2026-08-14)
- September 2027 — Trial primary completion: Phase 2 primary completion: A Study to Assess the Safety, Tolerability and Efficacy of ION775 (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 3 primary completion: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) (source, as of 2026-08-14)
- March 2029 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (source, as of 2026-08-14)
- June 2029 — Trial primary completion: Phase 3 primary completion: Donidalorsen Treatment in Children With Hereditary Angioedema (source, as of 2026-08-14)
- August 2029 — Trial primary completion: Phase 3 primary completion: An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) (source, as of 2026-08-14)
- August 2029 — Trial primary completion: Phase 3 primary completion: A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.